Results 41 to 50 of about 54,960 (249)

Radionuclide therapy in the treatment of thyroid malignancy [PDF]

Archive of Oncology, 2003
In this paper we presented the principles of performance of radionuclide therapy, its adverse effect, together with mentioned complications obligation to use it only according to directions and the success of the therapy, which is seen through the length
Malešević Milica Đ.
doaj   +1 more source

Combination Therapies with PRRT

Pharmaceuticals, 2021
Peptide receptor radionuclide therapy (PRRT) is a successful targeted radionuclide therapy in neuroendocrine tumors (NETs). However, complete responses remain elusive.
Anna Yordanova, Hojjat Ahmadzadehfar
doaj   +1 more source

Bisphosphonate-induced periprosthetic fracture: a cause of painful total hip arthroplasty [PDF]

, 2014
Background. Cases have been reported in the literature of periprosthetic fractures associated with the use of bisphosphonates occurring in the long term following a Total Hip Replacement (THR).
Bhattacharyya, Rahul, O’Neill, Gavin, Periasamy, Kumar, Spence, Stephanie   +3 more
core   +4 more sources

Issues and solutions in integrated radionuclide diagnosis and treatment [PDF]

Zhenduanxue lilun yu shijian
The integration of radionuclide diagnosis and treatment combines the dual functions of radionuclide imaging and treatment, and has been widely applied in the diagnosis and treatment of various tumors. Significant progress has been made in this field over
HONG Yena, ZHANG Yü, SHI Kuangyu, LI Biao, GUO Rui
doaj   +1 more source

NEMA NU 2-2007 performance characteristics of GE Signa integrated PET/MR for different PET isotopes [PDF]

, 2019
BackgroundFully integrated PET/MR systems are being used frequently in clinical research and routine. National Electrical Manufacturers Association (NEMA) characterization of these systems is generally done with F-18 which is clinically the most relevant
D'Asseler, Yves, De Vasconcelos Caribé, Paulo Rauli Rafeson, Deller, Timothy W, Koole, M., Van Laere, K, Vandenberghe, Stefaan   +5 more
core   +1 more source

Treatment options for PNET liver metastases. a systematic review [PDF]

, 2018
Pancreatic neuroendocrine tumors (PNETs) are rare pancreatic neoplasms. About 40-80% of patients with PNET are metastatic at presentation, usually involving the liver (40-93%). Liver metastasis represents the most significant prognostic factor.
Aurello, Paolo, Crovetto, Anna, Debs, Tarek, Mangogna, Livia Maria, Moschetta, Giovanni, Nigri, Giuseppe, Persechino, Raffaello, Petrucciani, Niccolò, Ramacciato, Giovanni   +8 more
core   +1 more source

Evaluation of radiological and clinical efficacy of ^{90}Y-DOTATATE} therapy in patients with progressive metastatic midgut neuroendocrine carcinomas [PDF]

, 2009
Background: To evaluate the radiological and clinical therapeutic effectiveness of ^{90}Y-octreotate [DOTATATE] inpatients with progressive somatostatin receptor-positive midgut neuroendocrine carcinomas (GEPNETs).
Buscombe, John R., Cwikła, Jaroslaw B., Jeziorski, Krzysztof G., Mikolajczak, Renata, Nasierowska-Guttmejer, Anna, Pawlak, Dariusz, Sankowski, Artur, Walecki, Jerzy   +7 more
core  

European Standard Clinical Practice Guideline and EXPeRT Recommendations for the Diagnosis and Management of Gastroenteropancreatic Neuroendocrine Neoplasms in Children and Adolescents

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Pediatric gastroenteropancreatic neuroendocrine neoplasms (GEP‐NENs) are extremely rare and clinically heterogeneous. Management has largely been extrapolated from adult practice. This European Standard Clinical Practice Guideline (ESCP), developed by the EXPeRT network in collaboration with adult NEN experts, provides (adult) evidence ...
Michaela Kuhlen, Calogero Virgone, Antje Redlich, Michael Abele, Ricardo Lopez‐Almaraz, Tal Ben‐Ami, Ewa Bien, Gianni Bisogno, Maja Mazic Cesen, Andrea Ferrari, Malgorzata A. Krawczyk, Yves Reguerre, Dominik T. Schneider, Ines B. Brecht, Charlotte Rigaud, Bilgehan Yalcin, Rainer Claus, Christian Vokuhl, Constantin Lapa, Jörg Fuchs, Segolene Hescot, Thomas Walter, Julien Hadoux, Daniel Orbach   +23 more
wiley   +1 more source

Treatment challenges in and outside a specialist network setting: Pancreatic neuroendocrine tumours [PDF]

, 2019
Pancreatic Neuroendocrine Neoplasms comprise a group of rare tumours with special biology, an often indolent behaviour and particular diagnostic and therapeutic requirements.
Almar E., Arveux P., Autelitano M., Baldi I., Bara S., Barchielli A., Benfatto L., Benhamou E., Bento M. J., Bielska-Lasota M., Blaszczyk J., Bordoni A., Botta L., Bouchardy C., Bouvier A. -M., Bouvier V., Brewster D. H., Calleja N., Candela P., Caplin M., Capocaccia R., Carulla M., Clough-Gorr K., Colonna M., Comber H., De Angelis R., de Lacerda G. F., de Munain A. L., Diaz Garcia J. M., Diba C. S., Dimitrova N., Dusek L., Engel J., Ess S. M., Falcini F., Falconi M., Ferretti S., Filiberti R. A., Fusai G. K., Fusco M., Galceran J., Gatta G., Gavin A., Gennaro V., Gentilini M., Giacomin A., Gozdz S., Grosclaude P., Guizard A. -V., Hackl M., Heidrich J., Henau K., Holleczek B., Huws D. W., Iannelli A., Johannesen T. B., Jonasson J. G., Kepska K., Knijn A., Konzelmann I., Kunkler I., Lapotre-Ledoux B., Larranaga N., Leinonen M., Luttmann S., Lykoudis P. M., Madeddu A., Magi M., Malila N., Mallone S., Mangone L., Marani E., Marcos-Gragera R., Maspero S., Maynadie M., Mazzoleni G., Michiara M., Miranda A., Molinie F., Monnereau A., Moreno-Iribas C., Mousavi M., Muffatti F., Navarro C., Nennecke A., Pannozzo F., Partelli S., Pierannunzio D., Piffer S., Pildava S., Primic-Zakelj M., Rachtan J., Rashbass J., Ricci P., Robaszkiewicz M., Rossi S., Rugge M., Salmeron D., Sanchez M. J., Santaquilani M., Sardo A. S., Schubert-Fritschle G., Schvartz C., Sekerija M., Sensi F., Serraino D., Smailyte G., Spagnoli G., Stabenow R., Stracci F., Tagliabue G., Tavilla A., Torrella-Ramos A., Trama A., Tretarre B., Troussard X., Tumino R., Usala M., Van Eycken E., Velten M., Visser O., Vitale F., Woronoff A. -S., Ziino A.   +123 more
core   +1 more source

Plant‐Produced Viral Nanoparticles Decorated with Nanobodies Against HER2 Improve Retention and Recruitment of Immune Cells in Solid Tumors

Advanced Healthcare Materials, EarlyView.
Potato virus X is a filamentous RNA plant virus that can be engineered into a molecular tool for cancer therapy. We produced genetically‐encoded virus‐derived nanoparticles decorated with nanobodies targeting cancer cell receptors, epidermal growth factor receptor (EGFR) and human epidermal growth factor 2 (HER2).
Enrique Lozano‐Sanchez, Miguel A. Moreno‐Gonzalez, Fernando Merwaiss, Nicole F. Steinmetz, José‐Antonio Daròs   +4 more
wiley   +1 more source